01 The Opportunity
02 The Solution
At the time of our first tour in summer 2021, the life sciences real estate market in Boulder was beginning to move in Enveda's favor. Several large, institutional landlords focused on acquiring and developing life sciences assets, were evaluating the purchase of major building portfolios in the Boulder market. Beacon Capital closed on the 900,000 SF Pearl East Business Park in early 2021 and BioMed Realty, one of the largest life sciences landlord developers in the world, was seriously considering a purchase of the 1 million SF Flatiron Park portfolio in East Boulder. Crescent Real Estate was the existing owner of Flatiron Park, and they were intent on completing a substantial life sciences transaction in the Park to help improve their park's value and solidify Flatiron Park as the premier biotech hub in Boulder. Our strategy was to leverage Beacon & Crescent's desire for a high-growth biotech tenant to create a competitive negotiation environment and drive as much value to Enveda as possible.